- Home
- Publications
- Publication Search
- Publication Details
Title
Chimeric Antigen Receptor T-cell Therapy for Melanoma
Authors
Keywords
-
Journal
Expert Review of Clinical Immunology
Volume -, Issue -, Pages -
Publisher
Informa UK Limited
Online
2021-01-23
DOI
10.1080/1744666x.2021.1880895
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy
- (2020) Magdalena Olbryt et al. Targeted Oncology
- CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead
- (2020) Qingyang Zhang et al. Journal of Immunology Research
- Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma
- (2020) Brendan Curti et al. Journal for ImmunoTherapy of Cancer
- Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial
- (2019) Ulrich Keilholz et al. Journal for ImmunoTherapy of Cancer
- Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System
- (2019) Shweta Joshi et al. Journal of Oncology
- Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
- (2019) Elizabeth I. Buchbinder et al. Journal for ImmunoTherapy of Cancer
- Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma
- (2019) Stephanie L. Goff et al. JOURNAL OF IMMUNOTHERAPY
- A phase 2 study of glembatumumab vedotin, an antibody‐drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma
- (2019) Patrick A. Ott et al. CANCER
- CAR T cells for brain tumors: Lessons learned and road ahead
- (2019) David Akhavan et al. IMMUNOLOGICAL REVIEWS
- CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia
- (2019) Dennis C. Harrer et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human
- (2019) Qian Sun et al. Cell Death & Disease
- Involvement of A2B Receptor in DNA Damage Response and Radiosensitizing Effect of A2B Receptor Antagonists on Mouse B16 Melanoma
- (2019) Yuta Tanaka et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Vemurafenib and cobimetinib‐induced toxic epidermal necrolysis in a patient with metastatic melanoma
- (2019) Sanja Poduje et al. Dermatologic Therapy
- Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy
- (2019) Sophia Stock et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
- (2019) Ahmad A. Tarhini et al. JOURNAL OF CLINICAL ONCOLOGY
- SOX2 upregulates side population cells and enhances their chemoresistant ability by transactivating ABCC1 expression contributing to intrinsic resistance to paclitaxel in melanoma
- (2019) Xiaoqiang Si et al. MOLECULAR CARCINOGENESIS
- Oncologic and visual outcomes after postoperative proton therapy of localized conjunctival melanomas
- (2019) Juliette Thariat et al. Radiation Oncology
- Role of Radiation in the Era of Effective Systemic Therapy for Melanoma
- (2019) A. Gabriella Wernicke et al. SURGICAL CLINICS OF NORTH AMERICA
- Roles of UVA radiation and DNA damage responses in melanoma pathogenesis
- (2018) Aiman Q. Khan et al. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS
- Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients
- (2018) Jiayi Yu et al. Journal of Hematology & Oncology
- Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy
- (2018) Shivani Srivastava et al. JOURNAL OF IMMUNOLOGY
- Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus–Driven Production of a Bispecific T-cell Engager
- (2018) Anna Wing et al. Cancer Immunology Research
- Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
- (2018) Samuel Rosner et al. Cancer Medicine
- Combining Adoptive Cell Therapy with Cytomegalovirus-Based Vaccine Is Protective against Solid Skin Tumors
- (2018) Jeremy M. Grenier et al. Frontiers in Immunology
- The application of CAR-T cell therapy in hematological malignancies: Advantages and challenges
- (2018) Zijun Zhao et al. Acta Pharmaceutica Sinica B
- Multidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant and neoadjuvant therapy
- (2018) Meredith A. McKean et al. CANCER TREATMENT REVIEWS
- Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma
- (2018) Shalin Shah et al. MELANOMA RESEARCH
- Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
- (2018) Sarwish Rafiq et al. NATURE BIOTECHNOLOGY
- Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer
- (2018) Michael Poch et al. OncoImmunology
- Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma
- (2018) Jun Zhang et al. Frontiers in Oncology
- Teaching an old dog new tricks: next-generation CAR T cells
- (2018) Nicholas Tokarew et al. BRITISH JOURNAL OF CANCER
- Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma
- (2018) Jinhuan Xu et al. Journal of Hematology & Oncology
- Melanoma subtypes: Genomic profiles, prognostic molecular markers and therapeutic possibilities
- (2018) Roy Rabbie et al. JOURNAL OF PATHOLOGY
- Adoptive cellular therapies: the current landscape
- (2018) Maartje W. Rohaan et al. VIRCHOWS ARCHIV
- Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy
- (2018) James Sun et al. OncoTargets and Therapy
- Advances in Immunotherapy for Melanoma: A Comprehensive Review
- (2017) Carmen Rodríguez-Cerdeira et al. MEDIATORS OF INFLAMMATION
- Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor
- (2017) Jonathan Fisher et al. MOLECULAR THERAPY
- The Role of Surgery for Melanoma in an Era of Effective Systemic Therapy
- (2017) Siavash Raigani et al. Current Oncology Reports
- Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment
- (2017) Irene Scarfò et al. Journal for ImmunoTherapy of Cancer
- Melanoma-specific mortality and competing mortality in patients with non-metastatic malignant melanoma: a population-based analysis
- (2016) Weidong Shen et al. BMC CANCER
- Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy
- (2016) M. V. Maus et al. CLINICAL CANCER RESEARCH
- Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
- (2016) Leonid Cherkassky et al. JOURNAL OF CLINICAL INVESTIGATION
- Toxicity and management in CAR T-cell therapy
- (2016) Challice L Bonifant et al. Molecular Therapy-Oncolytics
- Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone
- (2015) Christian Krug et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma
- (2015) J. Krishnamurthy et al. CLINICAL CANCER RESEARCH
- The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
- (2015) Kathleen M. Mahoney et al. CLINICAL THERAPEUTICS
- Inhibition of the ERCC1–XPF structure-specific endonuclease to overcome cancer chemoresistance
- (2015) Ewan M. McNeil et al. DNA REPAIR
- CAR T-cell therapy: toxicity and the relevance of preclinical models
- (2015) Milena Kalaitsidou et al. Immunotherapy
- Strategies for combining immunotherapy with radiation for anticancer therapy
- (2015) Steven N Seyedin et al. Immunotherapy
- Early detection of melanoma: Reviewing the ABCDEs
- (2015) Hensin Tsao et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic
- (2015) Connie P.M. Duong et al. MOLECULAR IMMUNOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy
- (2015) A. Holtzhausen et al. Cancer Immunology Research
- Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth
- (2015) Melanie Sweetlove et al. Frontiers in Oncology
- Clinical and prognostic factors for melanoma of the skin using SEER registries: Collaborative stage data collection system, version 1 and version 2
- (2014) Carol L. Kosary et al. CANCER
- A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States
- (2014) Lawrence Flaherty et al. CANCER JOURNAL
- Podoplanin expression in cancer-associated fibroblasts predicts aggressive behavior in melanoma
- (2014) Saori Kan et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Diverse Solid Tumors Expressing a Restricted Epitope of L1-CAM Can Be Targeted by Chimeric Antigen Receptor Redirected T Lymphocytes
- (2014) Hao Hong et al. JOURNAL OF IMMUNOTHERAPY
- Intratumoral CD4 + T Lymphodepletion Sensitizes Poorly Immunogenic Melanomas to Immunotherapy with an OX40 Agonist
- (2014) Susumu Fujiwara et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
- (2014) Jason Madore et al. Pigment Cell & Melanoma Research
- Emerging trends in the epidemiology of melanoma
- (2013) V. Nikolaou et al. BRITISH JOURNAL OF DERMATOLOGY
- Interleukin-7 Mediates Selective Expansion of Tumor-redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition
- (2013) S. K. Perna et al. CLINICAL CANCER RESEARCH
- Melanoma epidemiology, biology and prognosis
- (2013) Z. Ali et al. EJC SUPPLEMENTS
- Electrochemotherapy for the management of cutaneous and subcutaneous metastasis: A series of 39 patients treated with palliative intent
- (2013) Nicola Solari et al. JOURNAL OF SURGICAL ONCOLOGY
- Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia
- (2013) David S. Ritchie et al. MOLECULAR THERAPY
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Skin melanocytes: biology and development
- (2013) Mirosława Cichorek et al. Postepy Dermatologii i Alergologii
- Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
- (2012) W. Haso et al. BLOOD
- Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas
- (2012) Muhammad Baghdadi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy
- (2012) Richard C. Koya et al. CANCER RESEARCH
- Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients
- (2012) Eva Ellebaek et al. Journal of Translational Medicine
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006
- (2011) Ahmedin Jemal et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant radiation therapy in metastatic lymph nodes from melanoma
- (2011) Jean-Emmanuel Bibault et al. Radiation Oncology
- Anti-GD3 Chimeric sFv-CD28/T-Cell Receptor Designer T Cells for Treatment of Metastatic Melanoma and Other Neuroectodermal Tumors
- (2010) A. S. Y. Lo et al. CLINICAL CANCER RESEARCH
- Adjuvant Therapy With Agonistic Antibodies to CD134 (OX40) Increases Local Control After Surgical or Radiation Therapy of Cancer in Mice
- (2010) Michael J. Gough et al. JOURNAL OF IMMUNOTHERAPY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of radiotherapy in melanoma management
- (2010) Primoz Strojan Radiology and Oncology
- T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing
- (2010) Coen Govers et al. TRENDS IN MOLECULAR MEDICINE
- Glypican-3 protein expression in primary and metastatic melanoma
- (2009) Dina Kandil et al. CANCER CYTOPATHOLOGY
- Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines
- (2008) F. O. Smith et al. CLINICAL CANCER RESEARCH
- Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
- (2008) Alex J Eustace et al. Journal of Translational Medicine
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started